STANDING ORDER
NALOXONE PRESCRIPTION FOR OVERDOSE PREVENTION

Naloxone Hydrochloride (Naloxone) is a medication indicated for reversal of opioid overdose in the event of a drug overdose that is the result of consumption or use of one or more opioid-related drugs causing a drug overdose event.

I. PURPOSE
This standing order is intended to ensure that residents of the State of West Virginia who are at risk of experiencing an opioid-related overdose, or who are family members, friends or other persons who are in a position to assist a person at risk of experiencing an opioid-related overdose (Eligible Persons), are able to obtain Naloxone. This order is not intended to be used by organizations who employ or contract with medical staff who are authorized to write prescriptions. Organizations with a medical staff should rely on those medical professionals to write prescriptions or issue standing orders specific to the personnel who would be expected to administer Naloxone.

II. AUTHORITY
This standing order is issued pursuant to W.Va. Code § 16-46-7 (Senate Bill 272, amending the Access to Opioid Antagonists Act (2018 Regular Session)), which permits the State Health Officer, on a statewide basis, to prescribe an opioid antagonist by one or more standing orders to Eligible Persons.

III. AUTHORIZATION
This standing order may be used by Eligible Persons as a prescription or third-party prescription to obtain Naloxone from a pharmacy. This order is authorization for pharmacists to dispense Naloxone and devices for its administration SOLELY in the forms prescribed herein.

IV. ADMINISTRATION
Eligible Persons may administer, provide, or make available Naloxone to a person who the Eligible Person suspects of experiencing an opioid overdose event.

V. FORMULATION AND DIRECTIONS
Dispense two (2) doses of Naloxone Hydrochloride and necessary paraphernalia for administration. The specific Naloxone formulation shall be selected from the list below in accordance with the individual’s preference or training to administer a particular formulation.

1. For Intranasal Administration
   ➢ NARCAN® 4mg/0.1mL nasal spray. Include face shield for rescue breathing if available.

   Directions for use: Administer a single spray of NARCAN® in one nostril. Repeat after three (3) minutes if no or minimal response.

   Or
2mg/2mL single-dose Luer-Jet prefilled syringe. Include one luer-lock mucosal atomization device (MAD 300) per dose dispensed. Include face shield for rescue breathing if available.

**Directions for use:** Spray 1 mL in each nostril. Repeat after three (3) minutes if no or minimal response.

2. **For Intramuscular Injection**
   - 0.4mg/mL in 1mL single dose vials. Include one 3cc, 23g, 1” syringe per dose dispensed. Include face shield for rescue breathing and alcohol swabs if available.

   **Directions for use:** Inject 1 mL IM in shoulder or thigh. Repeat after three (3) minutes if no or minimal response.

3. **For Intramuscular or Subcutaneous Injection**
   - EVZIO® 2mg/0.4mL auto-injector, #1 Two-pack

   **Directions for use:** Follow audio instructions from device. Place on thigh and inject 0.4 mL. Repeat after three (3) minutes if no or minimal response.

**VI. REVIEW**
This standing order will be reviewed, and may be updated, if there is relevant new science about Naloxone administration, or at least in 4 years.

This standing order may be revised or withdrawn at any time

EXECUTED on this the 14th day of July, 2020.

Ayne Amjad, MD, MPH
Commissioner & State Health Officer
Bureau for Public Health